Previous 10 | Next 10 |
2024-05-11 06:58:33 ET Summary Organon, Pfizer, and Bristol Myers all offer yields above 5% and can compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial reversal of its decline since Merck's castoff h...
2024-05-10 12:55:34 ET As first-quarter earnings continue to march on, here is a recap of a few big names that posted their quarterly results, along with their respective commentaries about the future.... Read the full article on Seeking Alpha For further details see: A...
2024-05-09 12:00:10 ET Viatris Inc. (VTRS) Q1 2024 Earnings Call Transcript May 09, 2024, 08:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Conferen...
2024-05-09 08:15:00 ET Summary Teva Pharmaceutical stock has been trending higher since October 2023, closing at nearly $16.00. The company reported strong first-quarter results, with increased revenue and growth in key metrics. Teva has a positive business outlook for 2024, w...
2024-05-09 07:37:00 ET More on Viatris Inflation Reduction Act: A Bullish Catalyst For Viatris Inc. Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential Viatris Stock Is Still Worth Buying Viatris Non-GAAP EPS of $0.67 in-l...
2024-05-09 07:24:05 ET More on Viatris Inflation Reduction Act: A Bullish Catalyst For Viatris Inc. Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential Viatris Stock Is Still Worth Buying Viatris Non-GAAP EPS of $0.67 in-line, revenue of ...
2024-05-09 07:00:57 ET More on Viatris Inflation Reduction Act: A Bullish Catalyst For Viatris Inc. Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential Viatris Stock Is Still Worth Buying Viatris Q1 Earnings Preview: Focus remains on capital ...
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges PR Newswire PITTSBURGH , May 9, 2024 /PRNewswire/ -- Reports Total Revenues of $3.66 Billion ; U.S. GAAP Net Earnings of $113.9 Million ; Adju...
2024-05-08 13:03:54 ET Viatris ( NASDAQ: VTRS ) is scheduled to announce Q1 earnings results on Thursday, May 9th, before market open.... Read the full article on Seeking Alpha For further details see: Viatris Q1 Earnings Preview: Focus remains on capital allocation
2024-05-05 17:14:23 ET More on the Russell 2000: IWM A Bargain As The S&P 500's P/E Hits 21x It's Selling Season For The Russell 2000 And ETFs That Track It IWM: Are Small Caps Being Overlooked In The Megacap Market Frenzy? Broad market ETFs remain below ...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...